BACKGROUND-Robust comparisons of population-based cancer survival estimates require tight adherence to the study protocol, standardized quality control, appropriate life tables of background mortality, and centralized analysis. The CONCORD program established worldwide surveillance of population-based cancer survival in 2015, analyzing individual data on 26 million patients (including 10 million US patients) diagnosed between 1995 and 2009 with 1 of 10 common malignancies.
INTRODUCTION
Population-based cancer survival is a measure of the overall effectiveness of the health system in dealing with cancer. 1 Comparisons of population-based cancer survival require adherence to a well-designed protocol, standardized quality control procedures, appropriate life tables of background mortality, and centralized analysis with the latest statistical methods. 2, 3 The second cycle of the CONCORD program (CONCORD-2) established worldwide surveillance of cancer survival in 2015, with estimates of 5-year net survival based on individual data for more than 25 million cancer patients (approximately 10 million patients in the United States) diagnosed between 1995 and 2009 with 1 of 10 common cancers: stomach, colon, rectum, liver, lung, breast (women), cervix, ovary, prostate, and leukemia in adults (15-99 years old) and acute lymphoblastic leukemia in children (0-14 years old). 3 Patients were followed up to December 31, 2009. For the articles in this Cancer supplement, we analyzed data from 37 statewide cancer registries (27 funded by the National Program for Cancer Registries [NPCR] program, 5 funded by the Surveillance, Epidemiology, and End Results [SEER] program, and 5 funded by both NPCR and SEER) that participated in CONCORD-2. These registries, which cover approximately 80% of the US population, agreed to the inclusion of their data in more detailed analyses by stage at diagnosis and by race ( Fig. 1) . The CONCORD protocol required data on stage only for patients diagnosed from January 1, 2001 onward; these analyses, focusing mainly on survival by race and stage at diagnosis, were restricted to patients diagnosed between 2001 and 2009.
Public health surveillance using data from population-based cancer registries is a key component of cancer control. 4 The North American Association of Central Cancer Registries (NAACCR) develops and promotes uniform data standards for all cancer registries in North America. 5 Participating US registries had to meet the NAACCR certification criteria and to have conducted record linkage with both state vital records and the National Death Index to update the vital status of registered patients. NAACCR members developed a detailed SAS program to map the NAACCR database record structure to the CONCORD protocol and thus to enable all North American registries to exclude cases that would not have been considered reportable primaries according to the International Association of Cancer Registries' (IACR) multiple primary rules, 6 before their data sets for 1995-2009 were extracted for CONCORD-2. This was necessary because North American registries define multiple primary cancers under the rules of the SEER program, 7 whereas registries in the European Network of Cancer Registries and in other continents generally use the rules of the IACR, which are more conservative.
Topography and morphology were coded according to the International Classification of Diseases for Oncology, Third Edition (ICD-O-3). 8 Solid tumors were defined by anatomical site ( Table 1) . For ovarian cancer, we included the fallopian tube, uterine ligaments, and adnexa as well as the peritoneum and retroperitoneum, where high-grade serous ovarian carcinomas are often detected; this was done to improve the international comparability of the data sets. Kaposi's sarcoma and solid tumors with a lymphoma morphology were excluded from analysis.
Leukemias were defined by morphology. In this supplement, we cover only precursor-cell acute lymphoblastic leukemia in children (ICD-O-3 morphology codes 9727, 9728, 9729, 9835, 9836, and 9837). Estimates of survival by race, state, and subtype of adult leukemia will be presented in other publications.
Only primary invasive cancers (ICD-O-3 behavior code 3) were included in survival analyses. We included cancers at a given site regardless of whether the patient had had a previous cancer. If a patient had been diagnosed with 2 or more cancers of a given organ, including paired organs, between 2001 and 2009, only the first was considered in survival analyses.
FOLLOW-UP
US registries were asked to submit follow-up data (the vital status and the date of the last known vital status) as of December 31, 2009, after conducting linkages of all cancer registrations with both state vital records systems and the National Death Index. Patients whose cancer registration could not be linked to a death record were considered to be alive on December 31, 2009 (passive follow-up, which is also known as the "presumed alive" method).
have a date of last known vital status on or after January 1, 2010. These follow-up dates could have been obtained from either passive or active follow-up. 9 Patients whose survival time was unknown were excluded from analyses. This group comprised patients registered solely from a death certificate or diagnosed at autopsy.
DATA QUALITY CONTROL
We performed data quality checks in 3 consecutive phases: protocol adherence, exclusions, and editorial checks. After each phase, a detailed report was sent to each cancer registry.
Phase 1: Protocol Adherence
We first checked the compliance with the CONCORD-2 protocol of each of 37 variables (demographic characteristics, basis of diagnosis, date of diagnosis, topography, morphology, behavior, stage, vital status, and date of last known vital status) in each tumor record in each data set. Any value not specified in the protocol was considered noncompliant. Each registry was sent a table of the number of records and the percentage compliance for each variable and for each cancer. Minor issues were corrected by the CONCORD Central Analytic Team after discussion with the registry. For major structural issues, 5 registries corrected and resubmitted their data.
Phase 2: Exclusions
Next, we checked for logical inconsistencies between the variables in each tumor record, for each cancer site. Exclusion criteria were defined a priori on the basis of the experience within the Cancer Survival Group, the checks performed in the first CONCORD study, the data quality checks of EURO-CARE (a European cancer registry-based study of the survival and care of cancer patients), the checks proposed by the International Agency for Research on Cancer, the descriptions of morphology in the World Health Organization/International Agency for Research on Cancer classification of tumors for each cancer, and, finally, clinical expertise. 3 We produced exclusion tables summarizing the quality of each data set. Data quality indicators were tabulated separately for patients diagnosed in 1995-1999, 2000-2004, and 2005-2009 to enable evaluations of trends in data quality over time. We defined 3 broad categories for exclusion: ineligibility (eg, an in situ neoplasm), definite error (eg, a sex-site mismatch), and possible error (eg, an apparent inconsistency between site and morphology). We had requested records of in situ neoplasms to assess the intensity of diagnostic activity, particularly for cancers of the breast and cervix, but in situ neoplasms were not included in survival analyses. The number and percentage of patients excluded from analyses are shown in Table 2 .
The majority of the patients (99.6%) had only a single tumor record for any 1 cancer between 1995 and 2009. However, since a small proportion of patients had more than 1 tumor record for a given cancer ("multiple tumor, same site"), it was necessary to apply the quality control checks to every tumor record independently before we selected the single tumor record to be included in survival analyses. For example, if a woman had an in situ neoplasm of the breast diagnosed in 2001 followed by an invasive primary breast cancer in 2007, the invasive cancer record was selected for inclusion in the analyses as long as it was free of error.
Phase 3: Editorial Tables
We evaluated the distribution of key data quality indicators for each cancer and for each registry. These indicators included the proportion of cancers in the final data set that had been microscopically verified and the proportion of patients who had been lost to follow-up. We also checked the distributions of the day and the month of the dates of birth, diagnosis, and last known vital status. These distributions should be flat because one would expect approximately 8% of births, diagnoses, and deaths to occur in each month, and approximately 3% to occur on each day of a given month, except for days 29 to 31: spikes in these distributions, often on the 1st, 15th, or 16th day of the month, or in June or July, helped to identify where registries had imputed missing elements of each date. Table 2 provides a summary of the exclusions and data quality indicators for adults (15-99 years) diagnosed between 1995 and 2009 with 1 of 9 common cancers (all solid cancers), by US state. The calendar periods within which survival analyses could be performed by stage at diagnosis were constrained by the availability of data on stage only from 2001 onward, and by the change in coding from 2004 (discussed later). Therefore, the periods for which data quality indicators are presented do not exactly match the periods used for survival analysis. However, data quality has generally been very high in all US registries, and it tended to improve over the 15 years from 1995 to 2009. Only about 2% of tumors were registered from a death certificate only (DCO) or detected solely at autopsy. These records must be excluded from survival analyses because the follow-up time for these patients is unknown. However, the proportion of DCO registrations in the United States was low overall (1.9%) and in all states (range <0.1% to 3.5%). The proportion of other errors was very low (0.2%). Therefore, approximately 98% of eligible patients were included in survival analyses. Practically all tumors (99.7%) were microscopically verified: this proportion was more than 95% in almost all US states.
The proportion of the US population covered by this study is 80.6%. Table 3 shows the population coverage by US state, as well as the number of patients diagnosed between 1995 and 2009 and included in the analyses.
STUDY DESIGN
The focus of this monograph is the striking differences in survival by race and stage at diagnosis. Because differences in survival between men and women were generally very small compared to the differences in survival between blacks and whites (Table 4 ), we do not show survival estimates by sex in the articles on each cancer.
The CONCORD protocol required information on the stage at diagnosis only for patients diagnosed from 2001 onward, because the completeness of data on stage in the United States and many other countries was known to be much lower before 2001. For the analyses of survival by stage at diagnosis, patients were grouped by year of diagnosis into 2 calendar periods (2001-2003 and 2004-2009) to reflect changes in the methods used by US registries to collect data on the stage at diagnosis. From 2001 onward, most registries coded stage directly from the source data to SEER Summary Stage 2000. 10 From 2004 onward, all registries began to derive SEER Summary Stage 2000 from 15 pathological and clinical data items, using the Collaborative Staging System. 11 Data on stage at diagnosis were not available for Maryland or Wisconsin, or for patients diagnosed between 2004 and 2009 in Rhode Island.
We estimated net survival with the cohort approach for patients diagnosed in [2001] [2002] [2003] because all patients had been followed up for at least 5 years by December 31, 2009 . We used the complete approach to estimate net survival for patients diagnosed from 2004 to 2009 because 5 years of follow-up data were not available for all patients.
Cohort Approach
The cohort approach is the classic approach to survival analysis: all patients who are included in the analysis have had the opportunity to be followed for the full duration of the survival analysis (in this case, 5 years). The cohort of patients is defined by the year or calendar period during which they were diagnosed, and each patient is followed for the same length of time. In our analyses, at least 5 years of follow-up for vital status were available by the end of 2009 for all patients diagnosed between 2001 and 2003. Each patient, regardless of his or her actual year of diagnosis, contributes survival information at each point in follow-up time that, taken cumulatively, make up the survival estimate at 5 years.
The cohort approach is considered the gold standard 12, 13 because it provides a survival estimate for a group of patients who have been diagnosed during the same year or period, who are likely to have been treated in a similar fashion, and who have all been followed for at least the duration of survival required. It is the natural approach to estimation of the outcome and is easy to interpret, but other approaches may be required if sufficient data are not available.
Complete Approach
The complete approach can be applied to estimate survival for patients who have been diagnosed more recently, and for whom 5 full years of follow-up data may not be available at the closing date of the study. For example, some patients diagnosed in 2004-2009 were followed for less than 5 years. The cohort approach can be used to estimate 5-year survival for patients diagnosed in 2004, but 5-year survival can be estimated for the whole calendar period with the complete approach, in which all the available follow-up data for patients diagnosed between 2004 and 2009 are used. The potential follow-up time for these patients varies between 1 and 5 years.
Age Standardization
We compared survival estimates between US states, between blacks and whites, and between calendar periods of diagnosis. For age-specific survival estimates, a comparison between populations or over time is straightforward, but if we want to compare overall (all-ages) survival estimates, age standardization is required. This is essentially for the same reasons as in comparison of overall incidence or mortality rates, namely that net survival may also vary widely with age at diagnosis, and the age profile of cancer patients may differ between the populations or change between the calendar periods among which we wish to compare overall survival.
For age standardization of incidence or mortality rates, what matters is the age structure of the general population at risk of cancer. With cancer survival, however, what matters is the age profile of cancer patients, which is very different from the age profile of the general population. The weights used for age standardization of cancer survival estimates are thus completely different from those required for standardizing incidence or mortality rates. The weight for each age group is provided by the proportion of cancer patients in that age group in a standard population of cancer patients.
The International Cancer Survival Standard weights (ICSS) 14 are strongly recommended for international comparisons of cancer survival. They comprise 3 sets of standard age weights, derived from discriminant analysis to find the smallest number of sets of weights that enable adequate standardization of survival. Each standard is applicable to a range of different cancers, and provides age-standardized survival estimates that are not too different from the unstandardized estimates. The same age weights can be used for men and women, and for direct comparisons of age-standardized net survival between patient groups defined by sex and race.
STATISTICAL METHODS
We estimated net survival up to 5 years after diagnosis with 95% confidence intervals (CI), using the Pohar Perme estimator, implemented in the Stata algorithm. [15] [16] [17] We analyzed survival by state, race, stage at diagnosis, and calendar period of diagnosis. Net survival is the probability of surviving up to a given time since diagnosis after controlling for other causes of death (background mortality). To control for the wide differences in background mortality among participating states and racial/ethnic groups, we constructed life tables of all-cause mortality in the general population of each state from the number of deaths and the population by single year of age, sex, calendar year, and, where possible, race (black and white).
Net survival in adults was estimated for 5 age groups (15-44, 45-54, 55-64, 65-74, and 75-99 years; except for prostate cancer 15-54, 55-64, 65-74, 75-84 and 85-99 years). We obtained age-standardized survival estimates using the International Cancer Survival Standard weights. For children, survival was estimated for the age groups 0 to 4, 5 to 9, and 10 to 14 years. We obtained age-standardized estimates by assigning equal weights to the 3 age-specific estimates. 18 We derived standard errors for both unstandardized and age-standardized survival estimates with the Greenwood method, 19 assuming a normal distribution, and truncated to the range 0-100. We did not estimate survival if fewer than 10 patients were available for analysis. Age standardization was performed only if there were at least 10 patients in each of the age categories specified above. If an age-specific estimate could not be obtained, we merged data for adjacent age groups and assigned the combined estimate to both age groups. If 2 or more age-specific estimates could not be obtained, we present only the pooled, unstandardized estimates for all ages combined: these estimates are italicized in Supporting Tables 2 and 3 in other articles of this supplement. [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] For each of the 37 states, we present estimates of age-standardized net survival for each cancer up to 5 years after diagnosis. For convenience, we report cumulative survival probabilities (range, 0-1) as percentages in the range of 0% to 100%.
LIFE TABLES
For the analyses presented in this supplement, we used the life tables for background mortality that were constructed for the CONCORD-2 study. 30 To control for variation between US states in background mortality by age, sex, race, and calendar year while estimating net survival, we used life tables of all-cause mortality rates by single year of age (0-99 years) for each state, race, calendar year (2001-2010), and sex. For a few states in which the black population is small, it was not possible to construct adequately robust life tables of all-cause mortality by single year of age and sex for blacks, so net survival estimates for blacks in those states are not presented separately. These life tables can be downloaded from the CONCORD library of over 12,000 life tables. 31 The library includes detailed statistical and graphical reports on the robustness of the life tables for each US state.
We received raw data on death counts and populations for each US state. To produce life tables for each US state by race, sex, and calendar year (state-and race-specific life tables), we used a flexible Poisson model 32 that enables creation of single-year-of-age life tables even when the raw data are sparse. We checked the life tables by examination of semilog plots of the age-sex-mortality rates, the life expectancy at birth, the probability of death in the age bands 15 to 59, 60 to 84, and 85 to 99 years, and, where necessary, the model residuals, to examine the goodness of fit of the models by age and sex.
GRAPHICAL REPRESENTATION
In each cancer-specific article in this supplement, trends, geographic variations, and differences in age-standardized survival by race are presented graphically in bar charts and funnel plots. 33 
Bar Charts
Results are summarized in bar charts of 5-year age-standardized net survival by calendar period Each graphic includes the pooled survival estimates for all 37 participating states combined.
Funnel Plots
Funnel plots are graphical representations designed to detect excessive variation in performance indicators by simple visual inspection of the data. 34 They provide a simple and informative display of geographical variation or time trends in population-based cancer survival measures (eg, age-standardized net survival).
A funnel plot comprises 4 elements 33 : the target (or reference) value for the outcome, a set of control limits (the funnel), data points for the outcome variable (indicator), and the associated precision parameter for each data point. Data points outside the control limits (the funnel) indicate variation in the indicator beyond what would be expected by chance, while taking account of precision. 34 The funnel plot in Figure 2 shows, as an example, 5-year age-standardized net survival for breast cancer in the United States between 2004 and 2009, by race and state. It is constructed by plotting the 37 state-specific survival estimates for breast cancer between 2004 and 2009 (on the y-axis), against their associated precision (on the x-axis), forming a scatter plot. Fewer data points are available for blacks (28 states) than whites (37 states) because of the difficulty in constructing robust life tables for blacks in every state. The precision parameter in this example is, in fact, the precision of each age-standardized net survival estimate (the inverse of its variance). This is a natural choice to represent the statistical precision of each estimate, but it could be any function that is proportional to the inverse of the variance.
The target (the solid, horizontal line in Fig. 2) is then superimposed. This is a constant value, considered independent of the observations, and it specifies the expected value for the outcome. The target shown in Figure 2 is the 5-year age-standardized net survival estimate for the pooled US data for women diagnosed with breast cancer between 2004 and 2009. The pooled US estimate was selected as the target, to show the extent to which survival for blacks and whites in each state varies around the overall survival estimate for the United States.
The control limits (the dashed lines in Fig. 2 ) are also independent of the individual survival estimates. They depend only on the target value, and their correct formulation depends on the underlying theoretical distribution of the target value. The control limits for a given level of significance (α) are drawn around the target value across the entire observed range of precision of the individual estimates. The most common levels of significance are α = 5% and α = 0.2%, so the resulting 95% and 99.8% control limits represent approximately 2 and 3 standard deviations, respectively, on either side of the target value at each level of precision. An estimate that appears outside the control limits is identified as diverging from the target value and is an "out-of-control" estimate; in other words, it is a probable outlier that may need to be investigated further.
In Figure 2 , as with all the funnel plots reported in this supplement, 5-year age-standardized net survival is represented by open circles for white patients and by solid circles for black patients. Funnel plots are extremely powerful tools for visual examination of variation in an indicator: we can perceive at first glance that 5-year survival in blacks is persistently lower than would be expected (the pooled US survival estimate, ie, the target) and that survival for blacks is generally lower than survival for whites.
DISCUSSION
This article summarizes the data quality control procedures, analytic methods, and graphical presentations that have been deployed for all the data sets reported in this supplement. The quality of the population-based data from the 37 participating US cancer registries was impressively high (Table 2) . More details about the quality indicators for each cancer can be found in the online supplementary appendix (http://www.thelancet.com/journals/lancet/ article/PIIS0140-6736(14)62038-9/supplemental) for the CONCORD-2 article. 3 For NPCR registries that use only passive follow-up to determine the vital status of registered cancer patients (the "presumed alive" method), survival estimates may be inflated if the cancer registrations for some patients who have in fact died could not be successfully linked to the data from their death certificate. The vital statistics offices in each state have reported all death certificate information to the National Death Index since 1979. Passive methods of follow-up are known to be efficient because of the completeness and accuracy of the National Death Index, which tends to capture 1% to 3% more deaths than if the registry can link its data only to the state death index. 35 Most of the extra deaths captured in this way will be those of patients who migrated to a different state after their cancer diagnosis. However, the registries included in these analyses had all matched their data against the National Death Index before data submission, so the completeness of vital status ascertainment is expected to be extremely high, although it may not capture out-of-country deaths.
A major strength of this study is the use of life tables that are specific for each state, each race (white, black), and each calendar year, to control for differences and changes in background mortality by single year of age, sex, race, state, and single calendar year. This approach provided the tightest possible control of background mortality with the available data. More specific life tables may be considered in future studies, subject to the availability of high-quality data on death and population counts for Hispanics or other major racial or ethnic groups. This choice of calendar periods imposed the following selection of analytic approach. We were able to estimate 5-year net survival with the "cohort" approach for patients diagnosed in 2001-2003, since all patients had at least 5 years of potential follow-up. However, the "period" approach 36 that was adopted to estimate 5-year survival for patients diagnosed between 2005 and 2009 in the CONCORD-2 study 3 could have been used to estimate 5-year survival by stage for patients diagnosed between 2004 and 2009 only if stage data had also been available for patients diagnosed in 2000. We therefore adopted the "complete" approach. In this approach, more information is available for estimating survival in the early years of follow-up than for later years. Only patients diagnosed in 2004 had the potential to be followed up for 5 years by December 31, 2009 ; only patients diagnosed between 2004 and 2005 had the potential to contribute to the conditional survival probabilities between 4 and 5 years after diagnosis (and so on). This leads to some increased variation around the 5year survival estimates for 2004-2009 compared with those for 2001-2003. This is reflected in the confidence intervals, and slightly lower precision, seen in the funnel plots for 2004-2009 in some of the site-specific articles. This is the most extensive analysis of 5-year population-based cancer survival in the United States to date, with survival trends for 10 common cancers in 37 states that include 80% of the US population. Here, we have focused on variations in survival by race and stage at diagnosis for patients diagnosed between 2001 and 2009.
Population-based cancer survival is a key measure of the overall effectiveness of the health system in dealing with cancer. The high quality of the data from the US cancer registries, implementation of the most up-to-date and unbiased estimator of net survival, combined with the use of state-and race-specific life tables, all help to ensure that these cancer survival estimates are robust and comparable. We believe that they can be confidently used by policy-makers to identify inequities in cancer survival by race in each state and for the United States as a whole, and to plan cancer control strategies that promote equal opportunity for the best possible outcomes after a cancer diagnosis. Five-year age-standardized net survival for women (15- 
